In this video, Benjamin M. Brucker, MD, explains the use of clinical care pathways to manage overactive bladder and outlines the benefits of SUFU’s Overactive Bladder Clinical Care Pathway.
Overactive bladder (OAB) is a condition that deals with various aspects of health care, from conservative measures to medical therapies and advanced treatments. Thus, OAB lends itself to clinical care pathways, according to Benjamin M. Brucker, MD, of NYU Langone Health, New York.
“Without a clinical care pathway, patients often get frustrated, they fall into the trap of not necessarily realizing that there may be other therapies for them to utilize, and there are situations where they may have side effects, for example, from a medication that are very easy to rectify,” Dr. Brucker told Urology Times in this interview. “They just don’t have the tools to do so.”
In this video, Dr. Brucker explains the use of clinical care pathways to manage OAB, benefits of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Overactive Bladder Clinical Care Pathway, how this pathway is used in different types of patients and clinical settings, and work on a new SUFU OAB Pathway app for patients and physicians.
Dr. Brucker is a consultant/adviser to Allergan, Avadel, and Serenity, and conducts scientific studies/trials for Covance and Allergan.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.